Abeona Therapeutics Inc. (ABEO)

Market Cap	113.21M
Revenue (ttm)	3.57M
Net Income (ttm)	-38.72M
Shares Out	24.77M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,768
Open	4.52
Previous Close	4.56
Day's Range	4.46 - 4.61
52-Week Range	2.19 - 5.40
Beta	1.26
Analysts	Strong Buy
Price Target	29.00 (+537.36%)
Earnings Date	Nov 13, 2023

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO

Financial Performance

In 2022, ABEO's revenue was $1.41 million, a decrease of -52.87% compared to the previous year's $3.00 million. Losses were -$43.48 million, -48.81% less than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price forecast is $29.0, which is an increase of 537.36% from the latest price.

Price Target

$29.0

(537.36% upside)

Analyst Consensus: Strong Buy